Augmedix Awarded Vizient Contract For Ambient Ai Documentation Solutions

SAN FRANCISCO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Commure, a healthcare technology company, announced today that it has completed the acquisition of Augmedix. Augmedix will now operate as a wholly-owned subsidiary of Commure.

The merger was previously announced on July 19, 2024, and was approved by Augmedix stockholders at Augmedix’s special meeting of stockholders held on September 27, 2024. With the completion of the acquisition, Augmedix stockholders are entitled to $2.35 in cash for each share of Augmedix common stock they owned immediately prior to the closing. Augmedix’s stock has ceased trading and will be delisted from the Nasdaq Stock Market.

"I started Augmedix to relieve clinicians from administrative burdens that take them away from what matters most: patient care," said Ian Shakil, founder of Augmedix. "Joining forces with Commure allows us to scale that impact significantly."

Tanay Tandon, CEO of Commure, said, "Ian and the Augmedix team have done an incredible job as pioneers in the clinical documentation space. We’re thrilled to embark on this partnership to pair Augmedix’s deep expertise with our industry-leading suite of AI solutions."

For more information, visit commure.com.

About CommureCommure is a healthcare technology company based in Mountain View, California, providing AI-powered solutions to improve healthcare workflows and patient care.

About AugmedixAugmedix specializes in ambient medical documentation technology, helping clinicians reduce administrative tasks and focus more on patients.

Contact Information

For Commure:Daniel BrianEmail: daniel@commure.com

For Augmedix:Kaila GrafemanEmail: pr@augmedix.com

Cautionary Statement Regarding Forward-Looking Statements

This communication may contain forward-looking statements, which include all statements that do not relate solely to historical or current facts, such as statements regarding Augmedix’s impacts of the merger with Commure (the “Merger”), Augmedix’s delisting from the Nasdaq Stock Market, and other statements that concern Augmedix’s expectations, intentions or strategies regarding the future. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “aim,” “potential,” “continue,” “ongoing,” “goal,” “can,” “seek,” “target” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements are based on Augmedix’s beliefs, as well as assumptions made by, and information currently available to, Augmedix. Because such statements are based on expectations as to future financial and operating results and are not statements of fact, actual results may differ materially from those projected and are subject to a number of known and unknown risks and uncertainties, including, but not limited to: (i) the effect of the Merger on Augmedix’s business relationships, operating results and business generally; (ii) risks that the Merger disrupts Augmedix’s current plans and operations; (iii) Augmedix’s ability to retain and hire key personnel and maintain relationships with key business partners and customers, and others with whom it does business; (iv) risks related to diverting management’s or employees’ attention from Augmedix’s ongoing business operations; (v) the amount of costs, fees, charges or expenses resulting from the Merger; (vi) potential litigation relating to the Merger; (vii) risks that the benefits of the Merger are not realized when or as expected; (viii) continued availability of capital and financing and rating agency actions; and (ix) other risks described in Augmedix’s filings with the U.S. Securities and Exchange Commission (the “SEC”), such as the risks and uncertainties described under the headings “Cautionary Note Regarding Forward-Looking Statements,” “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other sections of Augmedix’s Annual Report on Form 10-K, Augmedix’s Quarterly Reports on Form 10-Q, and in Augmedix’s other filings with the SEC. While the list of risks and uncertainties presented here is considered representative, no such list or discussion should be considered a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and/or similar risks, any of which could have a material adverse effect on Augmedix’s consolidated financial condition. The forward-looking statements speak only as of the date they are made. Except as required by applicable law or regulation, Augmedix undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Sept 16 (Reuters) - Augmedix Inc AUGX.O:

• AUGMEDIX- RELATED TO DEAL WITH COMMURE GOT DEMAND LETTERS, A DEMAND TO INSPECT CO'S BOOKS AND RECORDS PURSUANT TO 8 DEL. C. § 220

• AUGMEDIX- RELATED TO DEAL WITH COMMURE, GOT TWO COMPLAINTS SENT ON BEHALF OF PURPORTED STOCKHOLDERS OF CO

• AUGMEDIX- 2 COMPLAINTS CHALLENGING ADEQUACY OF SOME DISCLOSURES MADE IN PRELIMINARY PROXY STATEMENT,DEFINITIVE PROXY STATEMENT FILED WITH SEC IN AUG

• AUGMEDIX- BELIEVES ALLEGATIONS IN STOCKHOLDER ACTIONS ARE "WITHOUT MERIT"

Source text for Eikon: [ID:n0001193125-24-219692]

Further company coverage: AUGX.O

(Reuters.Briefs@thomsonreuters.com)

NEW YORK, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Vector Group Ltd. (NYSE: VGR)’s sale to JT Group for $15.00 per share in cash. If you are a Vector shareholder, click here to learn more about your legal rights and options.

ConnectOne Bancorp, Inc. (NASDAQ: CNOB)’s merger with The First of Long Island Corporation. If you are a ConnectOne shareholder, click here to learn more about your legal rights and options.

Augmedix, Inc. (NASDAQ: AUGX)’s sale to Commure, Inc. for $2.35 per share in cash. If you are an Augmedix shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:Halper Sadeh LLCDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.com   https://www.halpersadeh.com

Bala Cynwyd, Pennsylvania--(Newsfile Corp. - September 12, 2024) - Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Augmedix, Inc. ("Augmedix" or the "Company") (NASDAQ: AUGX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the proposed sale of the Company to Commure, Inc. Under the terms of the agreement, Augmedix stockholders will receive $2.35 per share in cash upon completion of the proposed transaction.

The investigation concerns whether the Augmedix Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Commure is paying fair value to shareholders of the Company.

If you own shares of Augmedix stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at clients@brodsky-smith.com, visit https://www.brodskysmith.com/cases/augmedix-inc-nasdaq-augx-2/, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/223144

NEW YORK, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

Frontier Communications Parent, Inc. (NASDAQ: FYBR)’s sale to Verizon Communications Inc. for $38.50 per share in cash. If you are a Frontier shareholder, click here to learn more about your legal rights and options.

The First of Long Island Corporation (NASDAQ: FLIC)’s sale to ConnectOne Bancorp, Inc. for 0.5175 shares of ConnectOne common stock for each share of Long Island common stock. If you are a Long Island shareholder, click here to learn more about your legal rights and options.

Gatos Silver, Inc. (NYSE: GATO)’s sale to First Majestic Silver Corp. for 2.550 common shares of First Majestic for each common share of Gatos. Upon completion of the proposed transaction, Gatos shareholders will own approximately 38% of First Majestic shares on a fully-diluted basis. If you are a Gatos shareholder, click here to learn more about your legal rights and options.

Augmedix, Inc. (NASDAQ: AUGX)’s sale to Commure, Inc. for $2.35 per share in cash. If you are an Augmedix shareholder, click here to learn more about your rights and options.

Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:Halper Sadeh LLCDaniel Sadeh, Esq.Zachary Halper, Esq.(212) 763-0060sadeh@halpersadeh.comzhalper@halpersadeh.com   https://www.halpersadeh.com